Optimizing Personalized Pharmacotherapy in Managing Type 2 Diabetes: A Strategy to Mitigate Cardiovascular Risk

Abstract

Type 2 diabetes mellitus (T2DM) significantly elevates cardiovascular risk, necessitating personalized pharmacotherapeutic strategies. This study assesses the integration of advanced pharmacogenomics in tailoring diabetes management plans to mitigate cardiovascular complications. An observational cohort of 300 patients was analyzed, focusing on drug metabolism variance influenced by genetic polymorphisms. Our findings indicate that personalized medication regimens led to a 25% reduction in cardiovascular events over one year compared to standard treatments. This evidence underscores the importance of individualized approaches in mitigating the cardiovascular burden of T2DM, paving the way for enhanced therapeutic outcomes. In conclusion, implementing pharmacogenomic profiling in clinical practice can optimize drug efficacy and safety for diabetes patients at elevated cardiovascular risk.